Search Results for “study of the week” – Page 147

Editor’s Choice: The Intertwined Nature of Physical and Mental Health

Happy Thursday! This week, we're highlighting a PW contributor's story exploring blepharospasm and mental health and an article on two sisters with a rare connection. Following that, we have a…

Enrollment Fills Early for Phase 3 Trial of ALS Drug Candidate Arimoclomol

According to a press release from the Danish biopharmaceutical company Orphazyme, the Company has filled target enrollment for its phase 3 clinical study of arimoclomol in patients with amyotrophic lateral…

Glut1 Deficiency Foundation 2019 Conference Highlights!

I had the pleasure of attending the Glut1 Deficiency Foundation’s 2019 Conference. While this article can't possibly do the event justice and encompass all it had to offer, we will…

Otezla Receives FDA Approval for Treatment of Oral Sores that Characterize Behçet’s Disease

According to a press release from American biotechnology company Celgene Corporation, the American Food and Drug Administration (FDA) recently approved the Company's drug Otezla (generic name apremilast) for the treatment…

First Participant Dosed in Phase 1 Clinical Trial for Investigational Therapy for Multiple Sclerosis

Cyxone has just announced that the first person has been dosed in their Phase 1 clinical trial for Multiple Sclerosis (MS). This trial is investigating the effect of T20K. It…

‘No Cure, No Pay’ Model in the Netherlands Means Patients Don’t Pay Unless Their Therapy Works

No Cure, No Pay Emile Voest, an oncologist in the Netherlands, conceived the idea of a no cure, no pay model. After witnessing the exorbitant cost of drugs, some of…

FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug

According to a story from BioPortfolio, the biopharmaceutical company Genkyotex has recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application.…

Experimental Netherton Syndrome Treatment Receives Rare Pediatric Disease Designation from FDA

According to a press release from LifeMax Laboratories, Inc., the Food and Drug Administration (FDA) has granted the Company's experimental Netherton syndrome drug LM-030 (licensed from Novartis) Rare Pediatric Disease…